Chemotherapy and radiotherapy in Hodgkin's lymphoma: Joining in or splitting up?

Current Opinion in Oncology

Volumn 18, Issue 6, 2006, Pages 660-666

  Van Der Maazen, Richard W M ^a   Raemaekers, John M M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Hodgkin's lymphoma; Prevention of late effects; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORAMBUCIL; CHLORMETHINE; DEXAMETHASONE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; DIAGNOSTIC ACCURACY; HODGKIN DISEASE; HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HODGKIN DISEASE; HUMANS;

EID: 33748884503     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000245315.05263.fb     Document Type: Review

References (49)

1. Longo DL. Hodgkin disease: the sword of Damocles resheated. Blood 2004; 104:3418; Editorial.
2. Longo DL. Radiation therapy in Hodgkin disease: why risk a Pyrrhic victory? J Natl Cancer Inst 2005; 97:1394-1395.
3. Connors JM. State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol 2005; 23:6400-6408.
4. Yahalom J. Don't throw out the baby with the bathwater: on optimizing cure and reducing toxicity in Hodgkin's lymphoma. J Clin Oncol 2006; 24:544-548.
5. Guibout C, Adjadj E, Rubino C, et al. Malignant breast tumors after radiotherapy for a first cancer during childhood. J Clin Oncol 2005; 23:197-204.
6. Hill DA, Gilbert E, Dores GM, et al. Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors. Blood 2005; 106:3358-3365. A breast cancer case-control study (105 patients, 266 control subjects). Survivors of Hodgkin's lymphoma were included when treated at the age of 30 years or younger. Women who received radiotherapy exposure of more than 5 Gy had a 2.7-fold increased breast cancer risk. A family history of breast or ovarian cancer does not seem to lead to additional increased relative risks.
7. Das P, Ng AK, Stevenson MA, Mauch PM. Clinical course of thoracic cancers in Hodgkin's disease survivors. Ann Oncol 2005; 16:793-797.
8. Lorigan P, Radford J, Howell A, Thatcher N. Lung cancer after treatment for Hodgkin's lymphoma: a systematic review. Lancet Oncol 2005; 6:773-779.
9. Bowers DC, McNeil DE, Liu Y, et al. Stroke as a late treatment effect of Hodgkin's Disease: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2005; 23:6508-6515.
10. Heidenreich PA, Hancock SL, Vagelos RH, et al. Diastolic dysfunction after mediastinal irradiation. Am Heart J 2005; 150:977-982.
11. Hobbie WL, Ginsberg JP, Ogle SK, et al. Fertility in males treated for Hodgkin's disease with COPP/ABV hybrid. Pediatr Blood Cancer 2005; 44:193-196.
12. Mattle V, Behringer K, Engert A, Wildt L. Female fertility after cytotoxic therapy - protection of ovarian function during chemotherapy of malignant and nonmalignant diseases. Eur J Haematol 2005; 75 (Suppl. 66):77-82.
13. Hjermstad MJ, Fossa SD, Oldervoll L, et al. Fatigue in long-term Hodgkin's Disease survivors: a follow-up study. J Clin Oncol 2005; 23:6587-6595.
14. Mauch P, Ng A, Aleman B, et al. Report from the Rockefeller Foundation sponsored International Workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease: July 9-16, 2003, Bellagio, Italy. Eur J Haematol 2005; 75 (Suppl. 66):68-76. Recommendations for patients and physicians to reduce mortality and improve quality of life in long-term survivors of Hodgkin's lymphoma.
15. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835-3849.
16. Rehwald U, Schulz H, Reiser M, et al. Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 2003; 101:420-424.
17. Gobbi PG, Levis A, Chisesi T, et al. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 2005; 23:9198-9207.
18. Johnson PW, Radford JA, Cullen MH, et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol 2005; 23:9208-9218.
19. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23:4634-4642. Randomized comparison of chemotherapy alone with combined modality treatment in patients with limited-stage Hodgkin's lymphoma (399 patients, 4.2 years median follow-up). Future updates will be very important with regard to late effects.
20. Eghbali H, Brice P, Creemers CP, et al. Comparison of three radiation levels after EBVP regimen in favourable supradiaphragmatic clinical stages I and II Hodgkin's lymphoma: Preliminary results of the EORTC-GELA H9F trial. Blood 2005; 106:240a; Abstract.
21. Aleman BM, Raemaekers JM, Tirelli U, et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003; 348:2396-2406.
22. Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004; 104:3483-3489.
23. Laskar S, Gupta T, Vimal S, et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol 2004; 22:62-68.
24. Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002; 20:3765-3771.
25. Weiner MA, Leventhal B, Brecher ML, et al. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol 1997; 15:2769-2779.
26. Aviles A, Delgado S. A prospective clinical trial comparing chemotherapy, radiotherapy and combined therapy in the treatment of early stage Hodgkin's disease with bulky disease. Clin Lab Haem 1998; 20:95-99.
27. Fabian CJ, Mansfield CM, Dahlberg S, et al. Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease - A Southwest Oncology Group randomized study. Ann Intern Med 1994; 120:903-912.
28. Pavlovsky S, Maschio M, Santarelli MT, et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease. J Natl Cancer Inst 1988; 80:1466-1473.
29. Loeffler M, Brosteanu O, Hasenclever D, et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol 1998; 16:818-829.
30. Hicks RJ, Mac Manus MP, Seymour JF. Initial staging of lymphoma with positron emission tomography and computed tomography. Semin Nucl Med 2005; 35:165-175. Report on the use of FDG-PET as a biological predictive assay after two courses of chemotherapy in patients with Hodgkin's lymphoma.
31. Hutchings M, Loft A, Hansen M, et al. Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. Haematologica 2006; 91:482-489.
32. Spaepen K, Stroobants S, Dupont P, et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001; 115:272-278.
33. Zijlstra JM, Lindauer-van der WG, Hoekstra OS, et al. 18F-fluoro-deoxyglucose positron emission tomography for posttreatment evaluation of malignant lymphoma: a systematic review. Haematologica 2006; 91:522-529.
34. Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006; 91:475-481.
35. Hutchings M, Mikhaeel NG, Fields PA, et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005; 16:1160-1168.
36. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107:52-59. Report on the use of FDG-PET as a biological predictive assay after two courses of chemotherapy in patients with Hodgkin's lymphoma.
37. Eghbali H, Raemaekers J, Carde P. The EORTC strategy in the treatment of Hodgkin's lymphoma. Eur J Haematol 2005; 75 (Suppl. 66):135-140.
38. Hoppe RT. The John Ultmann lecture - the role of radiation therapy in the treatment of Hodgkin's disease: past, present, and future. Eur J Haematol 2005; 75 (Suppl. 66):14-20.
39. Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21:3601-3608.
40. Shahidi M, Kamangari N, Ashley S, et al. Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease. Radiother Oncol 2006; 78:1-5.
41. Girinsky T, Pichenot C, Beaudre A, et al. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? Int J Radiat Oncol Biol Phys 2006; 64:218-226.
42. Goodman KA, Toner S, Hunt M, et al. Intensity-modulated radiotherapy for lymphoma involving the mediastinum. Int J Radiat Oncol Biol Phys 2005; 62:198-206.
43. Yahalom J. Transformation in the use of radiation therapy of Hodgkin lymphoma: new concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT). Eur J Haematol 2005; 75 (Suppl. 66):90-97.
44. Canellos GP. Clinical trials in North America. Eur J Haematol 2005; 75 (Suppl. 66):121-124.
45. Josting A, Heidecke C, Dieh V. Overview of the Sixth International Symposium on Hodgkin's disease-recent advances in basic and clinical trials. Eur J Haematol 2005; 75 (Suppl. 66):1-5.
46. Klimm B, Diehl V, Pfistner B, Engert A. Current treatment strategies of the German Hodgkin Study Group (GHSG). Eur J Haematol 2005; 75 (Suppl. 66):125-134.
47. Koontz BF, Kirkpatrick JP, Clough RW, et al. Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications. J Clin Oncol 2006; 24:605-611.
48. Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006; 24:3128-3135.
49. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339:1506-1514.